Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.55 |
| ▸ | RORC | P51449 | 6/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | RARG | P13631 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136872 | 0.89 | RORC (0.47) | MAPK8RORCRARGMEN1KMT2A | |
| SCHEMBL6136884 | 0.83 | RORC (0.66) | RORCRARGHPGD | |
| SCHEMBL6137028 | 0.80 | RORC (0.59) | RORCRARGSCN9AHPGD | |
| Hydrochloric Acid SCHEMBL6136775 | 0.79 | RORC (0.57) | RORCRARGHPGD | |
| Hydrochloric Acid SCHEMBL6136946 | 0.79 | RORC (0.57) | RORCRARGHPGD | |
| SCHEMBL6363756 | 0.78 | DGAT2 (0.41) | RORCSIGMAR1RARGMEN1KMT2A | |
| SCHEMBL6136871 | 0.75 | RORC (0.53) | RORCRARGMEN1KMT2AHPGD | |
| SCHEMBL6139715 | 0.75 | MEN1 (0.43) | MAPK8MEN1KMT2ANPSR1L3MBTL1 | |
| SCHEMBL6137351 | 0.75 | RORC (0.50) | RORCRARGSCN9AHPGD | |
| SCHEMBL12509562 | 0.75 | MAPK8 (0.52) | MAPK8RORCMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137960-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF NUCLEAR-PENETRATING ANTIBODIES | YALE UNIVERSITY | 2021-05-13 | — | — | US | disclosed |
| US-20050227299-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | AUER MANFRED | 2005-10-13 | — | — | US | disclosed |
| EP-1140856-B1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | NOVARTIS AG (CH) | 2005-04-27 | — | — | EP | disclosed |
| EP-1140856-A1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | Novartis AG (CH) | 2001-10-10 | — | — | EP | disclosed |
| US-20010005752-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | AUER MANFRED (AT) | 2001-06-28 | — | — | US | disclosed |
| US-6207831-B1 | A BENZOPYRAZOLE COMPOUND | NOVARTIS AG (CH) | 2001-03-27 | — | — | US | disclosed |
| WO-2000037448-A1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | NOVARTIS AG (CH) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010005752-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | SLC43A1, CUTA, ANXA1 | MAPK8 2803/4885RORC 4824/4885P2RY14 4430/4885 |
| US-20210137960-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF NUCLEAR-PENETRATING ANTIBODIES | KPNA1, KPNA2, KPNB1 | MAPK8 2205/4885RORC 1073/4885P2RY14 4261/4885 |
| US-20050227299-A1 | Fluorescent dyes (AIDA) for solid phase and solution phase screening | SLCO1A2, ABCG2, SLCO1B1 | MAPK8 3377/4885RORC 3437/4885P2RY14 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.